Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Hoa Nguyen who wrote (7328)	7/28/1998 6:34:00 PM
From: Hoa Nguyen	Respond to of 8116

CYTO's new web sites. I haven't seen this news article mentioned here, so I posted it below. I think the new web sites are very impressive. I hope they will help business. Hoa ------- PRINCETON, N.J., July 27 /PRNewswire/ -- CYTOGEN Corporation (Nasdaq: CYTO) today announced its new web sites cytogen.com and prostascint.com. These two new innovative web sites provide an interactive, informative look at CYTOGEN and its unique products and information directed to prostate cancer patients and physicians. www.cytogen.com offers a comprehensive look at CYTOGEN's services with special focus on marketed products. In addition to the corporate information, extensive information on Quadramet(R), the company's product approved for the treatment of bone pain resulting from cancer that has spread to the bone, is available for physicians, patients and other interested parties. www.prostascint.com is specifically focused on CYTOGEN's product, ProstaScint(R), a diagnostic imaging agent for newly diagnosed patients at high risk for the spread of prostate cancer and for post-prostatectomy patients with a high suspicion that the disease has recurred or spread. ProstaScint assists the physician in selecting the best course of treatment for the patient. Full prescribing information on Quadramet and ProstaScint can be found on their respective web sites. "The information on this web site for the more than eight million U.S. cancer survivors is very comprehensive," said Ellen L. Stovall, Executive Director, National Coalition for Cancer Survivorship. "Initiatives like this that can help cancer patients communicate more effectively with their physicians and that provide easy access to vital support groups are important to assist survivors in taking responsibility for their care and quality of their lives." Prostate cancer is the second leading cause of death from cancer in males in the United States. The American Cancer Society estimates there will be 184,500 new cases of prostate cancer in the United States in 1998. It is common in males over sixty and accounts for over 40,000 deaths annually. Among the web site features available to patients are the "Medical Minute," an interactive question and answer section; information on reimbursement and a reimbursement hotline; access to a tutorial on prostate cancer and one of the largest, searchable prostate cancer support group directories nationwide. Patients and families will have access to information on local meetings across the United States, including meeting times, meeting places and a contact to call in their location for more information. Physicians have the ability to post scans of their cases on a password- protected teleradiology section of the web site. This allows physicians to post images and exchange information with colleagues for the purposes of clinical or technical discussion. "We are pleased to be able to use emerging internet technologies to deliver essential information to cancer patients, physicians and the general community. We believe these web sites offer a comprehensive view of our commitment to cancer care," said Peter Bottini, Director of Information Technology and Webmaster at CYTOGEN. CYTOGEN is a biopharmaceutical company engaged in the development, manufacture and commercialization of products for the targeted delivery of diagnostics and therapeutic substances directly to disease sites. CYTOGEN has demonstrated its ability to develop new technology from early discovery through clinical development, regulatory approval and commercial scale biologic manufacturing. SOURCE CYTOGEN Corporation CONTACT: Corporate Communications of CYTOGEN, 609-987-8221, or Angela Bitting of Russell-Welsh, 650-312-0700, ext. 15, for CYTOGEN